In detail, NSCLC patients with elevated expression levels of ANLN, BMP2, CALU, COL1A1, COL1A2, COL3A1, LOXL2, MME, PTX3 and SLC2A1 had a poor prognosis. This evidence concerns the gene LOXL2 and non-small cell lung carcinoma.